Reviewers RWI information was distributed to the GWC and is published in this document (Appendix 2). This document was approved for publication by the gov- erning bodies of the ACC and the AHA and endorsed by the American Association for Clinical Chemistry, SCAI, and the STS. 1.4. Scope of the CPG The 2014 NSTE-ACS CPG is a full revision of the 2007 ACCF/AHA CPG for the management of patients with unsta- ble angina (UA) and non-ST-elevation myocardial infarc- tion (NSTEMI) and the 2012 focused update.8 The new title, Non-ST-Elevation Acute Coronary Syndromes, emphasizes the continuum between UA and NSTEMI. At presentation, patients with UA and NSTEMI can be indistinguishable and are therefore considered together in this CPG. In the United States, NSTE-ACS affects >625000 patients annually,* or almost three fourths of all patients with acute coronary syndrome (ACS).9 In selecting the initial approach to care, the term ischemia-guided strategy has replaced the pre- vious descriptor, initial conservative management, to more clearly convey the physiological rationale of this approach. The task of the 2014 GWC was to establish a contempo- rary CPG for the optimal management of patients with NSTE- ACS. It incorporates both established and new evidence from published clinical trials, as well as information from basic science and comprehensive review articles. These recommen- dations were developed to guide the clinician in improving outcomes for patients with NSTE-ACS. Table 2 lists docu- ments deemed pertinent to this effort and is intended for use as a resource, thus obviating the need to repeat extant CPG recommendations. The GWC abbreviated the discussion sections to include an explanation of salient information related to the recommenda- tions. In contrast to textbook declaratory presentations, expla- nations were supplemented with evidence tables. 